Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide

Feola, Mauro; Garrone, Ornella; Occelli, Marcella; Francini, Antonella; Biggi, Alberto; Visconti, G.; Albrile, Fabrizia; Bobbio, Marco; Merlano, Marco

doi:10.1016/j.ijcard.2009.09.564

Cited by 142 publications

(114 citation statements)

References 33 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Finally, three articles with incomplete data were excluded. The remaining 8 articles met all the inclusion criteria and the studies were, published between 2001 and 2014, with moderate-high study quality (1,(8)(9)(10)(11)(33)(34)(35). Table I shows the basic characteristics of included studies on the BNP serum level.…”

Section: Methodsmentioning

confidence: 99%

“…In the clinic, anthracycline-induced cardiotoxicity (AIC) is characterized as ventricular dysfunction with no symptoms in ≤57% of patients, and clinical heart failure after cardiomyopathy in ≤16% of the patients (3,6,7). In general, the risk of developing AIC is closely linked to the cumulative dose of anthracyclines (8,9). Furthermore, other factors such as age and gender may also contribute to the occurrence of AIC (1).…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, anthracyclines cause degeneration of ventricular muscles and consequently exhibit characteristics of congestive heart failure (26). More notably, anthracyclines can induce myocardial ischemia and increase pressure load (8). From these aspects, it is rational to postulate that serum BNP levels may be associated with AIC.…”

Section: Introductionmentioning

confidence: 99%

“…From these aspects, it is rational to postulate that serum BNP levels may be associated with AIC. Previous studies investigated the impact of serum BNP levels on the detection and prognosis of AIC, but their findings are contradictory (8,25), the present study endeavored to use a meta-analysis approach to examine the clinical value of serum BNP levels on the prediction and management of AIC.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity

2016

View full text Add to dashboard Cite

Abstract.Observational and experimental studies have produced inconsistent evidence about the association of serum levels of B-type natriuretic peptide (BNP) with anthracycline-induced cardiotoxicity (AIC). Therefore, the current meta-analysis examined the association between serum BNP levels and AIC by using data from high quality studies published in peer-reviewed journals. Relevant studies were identified through literature searches of China National Knowledge Infrastructure (CNKI), Web of Science, PubMed, Google Scolar and China BioMedicine (CBM). STATA software was used in this meta-analysis for statistical analysis. In addition, the crude standardized mean difference (SMD) with 95% confidence interval (CI) for the highest vs. the lowest category of serum BNP levels was calculated. A total of 8 independent case-control studies, containing 126 AIC patients and 569 healthy controls, were included for the current meta-analysis. The results indicated a significant difference in serum BNP levels between the cardiotoxic group and normal group, with respect to post-treatment and pretreatment with anthracyclines. Specifically, the serum levels of BNP increased remarkably after treatment with anthracyclines in the cardiotoxic group, compared with the normal group. No publication bias was detected in this meta-analysis. The findings of the present study provide strong evidence that serum BNP levels may be associated with AIC.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity

2016

View full text Add to dashboard Cite

show abstract

“…The most common reason for requesting RNV studies is to monitor possible cardiotoxicity caused by chemotherapeutic agents, such as the use of anthracycline-based chemotherapy to treat breast carcinoma in adults 2 and to treat Hodgkin disease (HD) in children. 3 Serial RNV studies of EF during therapy provide a sufficient means of avoiding drug-induced congestive heart failure.…”

mentioning

confidence: 99%

The motivation to reproject gated blood pool SPECT data as planar data

Nichols

Watson

2013

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

See related article, pp. 358-366In the current issue of the Journal, Wells et al, describe the results of deriving left ventricular (LV) ejection fraction (EF) values from planar radionuclide ventriculography (RNV) images that are not conventionally obtained via best septal view planar imaging, but rather by reprojecting gated blood pool SPECT data as planar RNV images.1 This is a topic of relevance for laboratories having SPECT-only cameras which are requested to perform gated blood pool scans.The most common reason for requesting RNV studies is to monitor possible cardiotoxicity caused by chemotherapeutic agents, such as the use of anthracycline-based chemotherapy to treat breast carcinoma in adults 2 and to treat Hodgkin disease (HD) in children. 3Serial RNV studies of EF during therapy provide a sufficient means of avoiding drug-induced congestive heart failure. 4 Some published guidelines for evaluating anthracycline cardiotoxicity in children advocate using both echocardiography and planar RNV studies.5 However, as treatment protocols can extend over several weeks or months, serial evaluations of EF are required, so that in general serial measurement of EF for children is performed by echocardiography, 5 but for adults is performed by planar RNV as it has been considered the best non-invasive EF method. 6 Subjects can be followed for 10 years or more because features of abnormal cardiac function will sometimes appear only many years later after completion of treatment. Planar EFs have long been the desired means of evaluating EFs because of the simplicity of the imaging conditions. Planar RNV imaging also provides diastolic filling parameters, which progressively deteriorate with anthracycline therapy, along with phase histograms and fairly robust visual images that can be used for quality control and to corroborate significant changes in the value of EF. In terms of acquiring images, it is relatively undemanding to identify the angle for the best planar septal LAO view. In terms of processing acquired data, automated algorithms are often successful at generating LV and background regions that are satisfactory, but when they require manual correction, the process of manually drawing a ROI to isolate LV activity is fairly straightforward. So, it is the simplicity of the imaging setup in combination with the simplicity of data analysis that facilitates reproducible EF values. It is considered feasible to obtain planar EF values with a reproducibility of 4-5%. 9,10 No test is perfect, and the shortcomings of planar RNV imaging have long been recognized. Because red blood cells in the lungs in front of and behind the LV contribute to cross talk counts, along with scattered radiation from other non-ventricular structures, counts in the ROI intended to isolate the LV may be contaminated. Subtracting average background counts as estimated using neighboring regions helps to correct for tissue cross talk, but the major impediment to planar RNV EF absolute accuracy is variability from one patient to another in the d...

show abstract

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology

Pudil

Mueller

Čelutkienė

et al. 2020

European J of Heart Fail

240

182

View full text Add to dashboard Cite

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio‐Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio‐Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2‐targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio‐oncology biomarker research is discussed.

show abstract

Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide

Cited by 142 publications

References 33 publications

Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity

Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity

The motivation to reproject gated blood pool SPECT data as planar data

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology

Contact Info

Product

Resources

About